Risk of tuberculosis reactivation with tofacitinib (CP-690550).
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22474037.
- Also identified by DOI 10.1093/infdis/jis269 and PMC identifier 3415851.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.
Medical subject headings
- Anti-Inflammatory Agents
- Immunologic Factors
- Pyrimidines
- Pyrroles
- Tuberculosis